Kidney cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 21
• PD-L1 11
• VEGF 10
• mTOR 1
• AKT 0
• VHL 6
• PI3K 0
• PSMA 10
• STAT3 0
• BAP1 1
• TP53 0
• JAK 0
• CTLA-4 4
• STING 1
• ALK 1
• EGFR 3
• TFEB 0
• ERK 0
• MYC 0
• YAP 0
• HIF-1 0
• AMPK 0
• CTNNB1 0
• MET 2
• B7-H3 2
• MAPK 0
• PPAR 0
• FGFR 1
• GLP-1 0
• GPC3 3
• HER2 2
• IL-6 0
• MMP-9 0
• PARP 1
• AXL 1
• BCL-2 0
• EZH2 0
• IDH 1
• NTRK 0
• PTEN 0
• BRAF 1
• CD19 1
• CDKN2A 0
• JNK 0
• KRAS 1
• LAG-3 0
• METTL3 1
• NLRP3 0
• NRF2 0
• PKM2 0
• ROS1 0
• TNF 0
• APOE 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CD20 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0

24 of 63+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · K99

  Defining how mitochondrial metabolites reprogram cellular metabolism to control tumor growth

  Northwestern University· Chicago, United States· US$99,022 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R50

  Research specialist award to support PDIGREE (A031704) and implementation of NCI supported clinical trials at Simmons Comprehensive Cancer Center

  Ut Southwestern Medical Center· Dallas, United States· US$164,513 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R44

  Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors

  Rise Therapeutics, Llc· Rockville, United States· US$740,140 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · R01

  Fasting mimicking diet and cancer stem cells in Wilms tumor

  Children's Hospital of Los Angeles· Los Angeles, United States· US$739,756 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Southern Community Cohort Study

  Vanderbilt University Medical Center· Nashville, United States· US$1,249,181 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Identification of TILs-specific novel lincRNA and their functional importance in mediating immune response in renal cell carcinoma (REGULINC)

  Turun Yliopisto· Turku, Finland· EU contribution €226,277· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  IDENTIfication and tracking of cancer-prone cells in KIdney Tubules (IDENTIKIT)

  Universita Vita-Salute San Raffaele· Milano, Italy· EU contribution €1,500,000· until Dec 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  TARGETING INHERITED CANCER SYNDROMES (INCANTAR)

  Fondazione Telethon Ets· Roma, Italy· EU contribution €2,496,625· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-RIA

  First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma (CARE1)

  Institut Gustave Roussy· Villejuif, France· EU contribution €5,577,694· until Apr 2028· 14 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  COMputational Models FOR patienT stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care (COMFORT)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €5,906,596· until Mar 2027· 7 countries

10 of 245 running projects, newest first. Listed amounts together: US$130.4m + €19.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

  NCT05935748· NiKang Therapeutics, Inc.· Updated 12 Nov 2026

  “This study was terminated as a result of Sponsor portfolio reprioritization.”Registry text, quoted unchanged. Source

• Terminated

  High Dose IL-2 in Combination With Anti-PD-1

  NCT03991130· Gregory Daniels· Updated 6 Aug 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

  NCT04955743· Yale University· Updated 4 Jun 2026

  “Lack of activity in the drugs”Registry text, quoted unchanged. Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

• Terminated

  ITIL-306 in Advanced Solid Tumors

  NCT05397093· Instil Bio· Updated 15 Apr 2026

  “The study was terminated early due to discontinuation of development of the investigational program”Registry text, quoted unchanged. Source

• Terminated

  A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

  NCT06580938· Pfizer· Updated 23 Mar 2026

  “The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns”Registry text, quoted unchanged. Source

• Terminated

  A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

  NCT06546553· Pfizer· Updated 23 Feb 2026

  “Study terminated as part of strategic considerations and not based on safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Updated 12 Jan 2026

  “Business Decision”Registry text, quoted unchanged. Source

• Terminated

  A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

  NCT06285097· Pfizer· Updated 17 Sept 2025

  “The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

  NCT05155033· National Cancer Institute (NCI)· Source

• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

  NCT04736706· Merck Sharp & Dohme LLC· Source

• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  NCT03972657· Regeneron Pharmaceuticals· Source

• Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

  NCT04704219· Merck Sharp & Dohme LLC· Source

• Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Arcus Biosciences, Inc.· Source

• Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Merck Sharp & Dohme LLC· Source

• Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Merck Sharp & Dohme LLC· Source

• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

  NCT05899049· Merck Sharp & Dohme LLC· Source

• A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

  NCT06307431· Merck Sharp & Dohme LLC· Source

• A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

  NCT05239728· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 37
• Organoids 4
• Mendelian Randomization Analysis 22
• CRISPR-Cas Systems 8
• Gene Expression Profiling 97
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 10
• Proteomics 25
• Metabolomics 12
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 95
• Liquid Biopsy 6
• Circulating Tumor DNA 8
• Xenograft Model Antitumor Assays 77
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 60
• Machine Learning 71
• Deep Learning 36
• Cohort Studies 67
• Genome-Wide Association Study 19

• Integrated single-cell and bulk transcriptomic analyses reveal ferro-aging-related molecular characteristics and immunological heterogeneity in renal cell carcinoma.

  PLoS One, Nov 2026

• Integrative Molecular Profiling and Single-Cell Characterization of LHFPL5 Reveal Cancer-Specific Regulatory Features in Clear Cell Renal Cell Carcinoma and Lung Adenocarcinoma.

  Medicina (Kaunas), Oct 2026

• Single-cell transcriptomics combined with Mendelian randomization reveals the pivotal role of WDR83OS in clear cell renal cell carcinoma: An observational and bioinformatic study.

  Medicine (Baltimore), Sept 2026

• Single-cell profiling of mitochondrial phenotyping-coupled mtDNA genotyping.

  Proc Natl Acad Sci U S A, Aug 2026

• Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma.

  Nat Commun, Aug 2026

• Integrating single-cell analysis and machine learning algorithms to explore lactylation-related molecular mechanisms and therapeutic responses in clear cell renal cell carcinoma and identifying CDT1 as a potential biomarker.

  Front Endocrinol (Lausanne), Aug 2026

• Single-Cell and Machine Learning Analyses Identify MYDGF as an Immune-Related Biomarker Associated With the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.

  Hum Mutat, Jul 2026

• Bulk and single-cell transcriptome-based integrative analysis of an rRNA processing-related prognostic signature with functional validation of DDX47 in clear cell renal cell carcinoma.

  BMC Cancer, Jul 2026

• Computational analysis of bulk and single-cell RNAseq identifies prognostic signature genes in papillary renal cell carcinoma with Y chromosome loss.

  Comput Biol Med, Jun 2026

• Employing network toxicology, molecular docking, machine learning, and single-cell analysis to analyze BPA exposure-induced ccRCC.

  Biochem Biophys Res Commun, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.